Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
1(25.0%)
Phase 4
1(25.0%)
4Total
Phase 2(2)
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07444502Completed

Safety Monitoring of Boostagen® Vaccine in Thailand

Role: lead

NCT07400120Completed

Safety Monitoring of VacPertagen Vaccine in Thailand

Role: lead

NCT07213089Phase 2Completed

Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers

Role: lead

NCT06888076Active Not Recruiting

Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Pregnant Women

Role: lead

NCT06798831Phase 3Active Not Recruiting

Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Adults

Role: lead

NCT06803524Phase 4Recruiting

10-year Follow-up After a Single Dose Acellular Pertussis Vaccination

Role: collaborator

NCT04529720Completed

5-year Follow-up After a Single Dose Acellular Pertussis Vaccination

Role: collaborator

NCT02946190Phase 2Completed

The PertADO Geneva Trial

Role: collaborator

All 8 trials loaded